Cure TV

An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.

After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.

Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt.

Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.

Outpatient CAR T therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.

Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.

Dr. Erika Hamilton discusses the most notable breast cancer treatments currently in development, and how might they change care for patients in the future.

The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.

A patient on the Monjuvi trial saw lymph nodes shrink 85%, with stable results a year later, supporting the FDA’s recent approval for follicular lymphoma.

Olalekan O. Oluwole discusses how CAR T-cell therapy is used to treat high-risk hematologic malignancies like lymphoma and leukemia.

Dr. Breelyn Wilky explains how vague symptoms and testing challenges delay GIST diagnoses; however, molecular testing can help guides treatment decisions.

Mark Daniels, an 83-year-old veteran and former fighter pilot, was shocked by his lymphoma diagnosis because he maintained exceptional physical fitness.

Ongoing research within the advanced-stage melanoma therapeutic space is beginning to suggest that shorter treatment periods may be sufficient for some.

Hearing that you have cancer can lead to dark feelings; however, others have walked this road and come out on the other end, a cancer thriver explained.

Dr. Nicholas James discusses why it is important to identify which patients with high-risk prostate cancer will truly benefit from intensified treatment.

Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.

Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.

Dr. Matthew Ku discusses what CAR T-cell therapy is and how it works to target diseases like myelofibrosis.

Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.

Dr. Breelyn Wilky stresses the importance of expert guidance and second opinions for patients with GIST, as treatment options continue to evolve rapidly.

Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.

An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns, per Dr. Lydia Scarfò.

Valarie Traynham shares what survivorship means to her, and how the definition has evolved after her diagnosis, during National Cancer Survivors Month.

Dr. Andre Henri Goy shared how CAR T-cell therapy led a retired pilot with lymphoma into remission, showing the impact of personalized treatment decisions.

Watch oncology dietitian Kanisha Parikh prepare creamy lentil soup, a soothing, protein-packed recipe to help ease side effects during treatment.

Waldenstrom macroglobulinemia is often slow growing, with high survival but lower quality of life over time, explained researcher Alisha Kimble.

Kasey Rangan discusses ways that families of patients with pediatric brain cancer can advocate for themselves, especially when it comes to mental health.

Dr. Joshua Sabari and Dr. Nausheen Ahmed sat down to discuss topline takeaways in the realm of hematologic malignancies following the 2025 ASCO Meeting.